HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Kimono Openings at Schering

Executive Summary

Disclosure may be an unwelcome visitor at Big Pharma, but formerly secretive executives are growing used to its demands, with some SEC encouragement. A recent 8K filing by Schering-Plough was as revealing as it was unusual. The company's recently disclosed contract with Merck on the co-development and co-promotion of cholesterol-lowering agent ezetimibe (Zetia) looks like a poison pill that will discourage a takeover of Schering.

You may also be interested in...

The Value of Me-Too's in the Context of OTC Switches

At Windhover's annual Marketing Pharmaceutical Innovation (MPI) conference in November, industry executives wrestled with an emerging dilemma -- how to win managed care's support for drugs that exhibit only minor improvements to existing products, while new over-the-counter (OTC) options surface.

Companies: Tell More, Sooner

If new disclosure rules proposed by the SEC become final as expected, they will make the Current Report Form 8-K filed by public companies more timely and more revealing--both about themselves and their partners. The rules stipulate 11 new reportable events, three of which are directly related to alliances, and the SEC also wants management to analyze the impact of the events they disclose. Life sciences lawyers say it's not fully clear what sorts of things companies in this sector will have to report: the impact of new 8-k rules will be decided with practice.

Health And Wellness Trademark Review 14 January, 2020

Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.


Related Companies

Related Deals




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts